Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Pain is an area with limited treatment options ... Last year’s Alpine acquisition added povetacicept to Vertex’s pipeline, which Vertex believes has a “pipeline in a product” potential.

Merck should be a useful partner for these, since it already has three oncology drugs on the market and eight in clinical trials in its pipeline. Journavx, Vertex’s nonopioid pain-signal ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Vertex Pharmaceuticals’ Jounavx is now FDA approved, providing patients a non-opioid option for treating acute pain. The twice ... aims to diversify with a pipeline that reaches more therapeutic ...

A decade from now, considering Vertex's pipeline, the company could potentially ... common problem that has limited treatment options: pain. Today's over-the-counter choices sometimes aren't ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals ... and much of that attributed to pipeline and pain opportunity, RBC remains ...

Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. VRTX ...